Method for altering insulin pharmacokinetics

• US 20060264886A9
• Filed: 05/06/2004
• Published: 11/23/2006
• Est. Priority Date: 05/06/2002
• Status: Abandoned Application

• Current Assignee: Becton, Dickinson & Co
• Original Assignee: Becton, Dickinson & Co
• Inventors: Pettis, Ronald J., Ginsberg, Barry, Harvey, Noel
• Application Number:
  US10/841,992
• Publication Number:
  US 20050055010A1
• Time in Patent Office: Days
• US Class Current: 604/500
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61M 5/46 having means for controlling depth of insertion

Abstract

The present invention relates to methods for administration of insulin into the intradermal compartment of subject'"'"'s skin, preferably to the dermal vasculature of the intradermal compartment. The methods of the present invention enhance the pharmacokinetic and pharmacodynamic parameters of insulin delivery and effectively result in a superior clinical efficacy in the treatment and/or prevention of diabetes mellitus. The methods of the instant invention provide an improved glycemic control of both non-fasting (i.e., post-prandial) and fasting blood glucose levels and thus have an enhanced therapeutic efficacy in treatment, prevention and/or management of diabetes relative to traditional methods of insulin delivery, including subcutaneous insulin delivery.

Claims

1. A method for administration of an insulin formulation to a human subject, comprising delivering the insulin formulation into an intradermal compartment of the human subject'"'"'s skin, so that the insulin formulation is deposited at a depth of 1.25 mm.

4. The method of any of claims 1-3 wherein the insulin formulation is in solution form.

5. The method of claim 4, wherein the insulin formulation is Humalog®

.

6. The method of claim 4, wherein the insulin formulation is in particulate form.

7. The method of claim 6, wherein the insulin formulation is Humalog®

Mix 50/50™

.

8. The method of any of claims 1-3, wherein the onset of systemically available insulin delivered is more rapid compared to subcutaneous delivery.

9. The method of any of claims 1-3, wherein the method results in a faster and greater change in the blood glucose levels compared to subcutaneous delivery.

17. The method of any of claims 1-3, wherein the biopotency of insulin is increased by 60% compared to subcutaneous delivery.

3. A method for administration of an insulin formulation to a human subject, comprising delivering the insulin formulation into an intradermal compartment of the human subject'"'"'s skin, so that the insulin formulation is deposited at a depth of 1.75 mm.

10. A method for administration of an insulin formulation to a human subject, comprising delivering the insulin formulation into an intradermal compartment of the human subject'"'"'s skin, wherein the insulin formulation comprises a mixture of solution and particulate forms and wherein the particulate form is from about 1% to about 99% of the total formulation, so that the insulin formulation is deposited at a depth of 1.25 mm.

11. A method for administration of an insulin formulation to a human subject, comprising delivering the insulin formulation into an intradermal compartment of the human subject'"'"'s skin, wherein the insulin formulation comprises a mixture of solution and particulate forms and wherein the particulate form is from about 1% to about 99% of the total formulation, so that the insulin formulation is deposited at a depth of 1.5 mm.

12. A method for administration of an insulin formulation to a human subject, comprising delivering the insulin formulation into an intradermal compartment of the human subject'"'"'s skin, wherein the insulin formulation comprises a mixture of solution and particulate forms and wherein the particulate form is from about 1% to about 99% of the total formulation, so that the insulin formulation is deposited at a depth of 1.75 mm.

13. A method for administration of an insulin formulation in particulate form to a human subject, comprising delivering the insulin formulation into an intradermal compartment of the human subject'"'"'s skin, so that the insulin formulation is deposited at a depth of 1.25 mm.

16. The method of any of claims 13-15, wherein the administered insulin has a lower T_max, a higher C_max, and a higher bioavailability, compared to subcutaneous delivery.

14. A method for administration of a insulin formulation in particulate form to a human subject, comprising delivering the insulin formulation into an intradermal compartment of the human subject'"'"'s skin, so that the insulin formulation is deposited at a depth of 1.5 mm.

15. A method for administration of a insulin formulation in particulate form to a human subject, comprising delivering the insulin formulation into an intradermal compartment of the human subject'"'"'s skin, so that the insulin formulation is deposited at a depth of 1.75 mm.

18. The method of any of claims 1-3, wherein the insulin delivered results in reduction of post-prandial glucose levels by at least 20 mg/dL.

2. A method for administration of an insulin formulation to a human subject, comprising delivering the insulin formulation into an intradermal compartment of the human subject'"'"'s skin, so that the insulin formulation is deposited at a depth of 1.5 mm.

19. The method of any of claims 1-3, wherein the insulin delivered results in reduction of post-prandial glucose levels by at least 30 mg/dL.

18-1. A method of eliciting a prolonged circulation of insulin in a human subject, comprising delivering into an intradermal compartment of the human subject'"'"'s skin an insulin formulation which comprises both particulate and solution forms of insulin.

19-2. The method of claim 18, wherein the onset of systemically available insulin delivered is more rapid compared to subcutaneous delivery.

20. The method of any of claims 1-3, wherein the insulin delivered results in reduction of post-prandial glucose levels by at least 45 mg/dL.

22. The method of claim 20 or 21, wherein the onset of systemically available therapeutic agent delivered is more rapid compared to subcutaneous delivery.

20-3. A method of modulating circulation half life of insulin in a human subject, comprising administering into an intradermal compartment of the human subject'"'"'s skin a composition comprising both particulate and solution forms of insulin, wherein the ratio between the particulate and solution forms of the therapeutic agent is varied.

21. A method of modulating circulation half life of a therapeutic agent in a human subject, comprising administering into an intradermal compartment of the human subject'"'"'s skin a composition comprising both particulate and solution forms of the therapeutic agent, wherein the ratio between the particulate and solution forms of the therapeutic agent is varied.

23. The method of claim 21, wherein the therapeutic agent is a protein.